Blog | Veristat, The Science-First CRO

Gain the latest insights and trends in clinical trials, patient recruitment, data analysis, adaptive design, regulatory submissions and approvals.

Sign Up Today

Bold Thinking that Delivers Results for RNA Therapies

Current advances in RNA-based therapies hold substantial promise in treating and preventing many human diseases and disorders through curing the disease, rather than treating the symptomology like traditional therapeutics.

READ MORE

CMC Pitfalls: From Benchtop to IND

Successfully transitioning from academic or bench-top production to manufacture clinical-grade material is not an easy feat. There are many factors new sponsors must consider when determining readiness to file an Investigational New Drug (IND) from a...

READ MORE

2 min read

FDA Introduces New Term "Nonclinical Tests" Signaling a Beginning, Not an End

For the past 60 years, US law has empowered the FDA to require that clinical trial sponsors submit data from “preclinical tests ” to prove their drug is safe enough to advance to testing in humans. At the close of last year, Food and Drug Omnibus Reform...

READ MORE

4 min read

Regulatory Guidance Monthly Review - February 2023

Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA) that are pertinent to the governance of clinical trials and drug, biologic, or medical device development...

READ MORE

1 min read

European Medicines and Medical Devices: Future Trends

Based on an online seminar presentation made in collaboration with TOPRA and Veristat, this article dives into the future of the European medicines and medical devices industry and the changes in legislation that are being prompted by the evolving...

READ MORE

Emergency Use Authorizations

Emergency Use Authorizations (EUA) are a mechanism that allows the U.S. FDA to facilitate the availability of medical countermeasures for chemical, biological, radiological, and nuclear (CBRN) threats, including emerging infectious diseases such as...

READ MORE

1 min read

Podcast: Orphan Drug Designations and Orphan Subsets

Sponsors developing drugs or biologics intended to prevent, diagnose, or treat a rare disease or condition should consider applying for the Orphan Drug Designation (ODD) program with the FDA. The FDA’s Orphan Drug Designation program is meant to...

READ MORE

4 min read

Regulatory Guidance Monthly Review - January 2023

Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA) that are pertinent to the governance of clinical trials and drug, biologic, or medical device development...

READ MORE

4 min read

Weighing the Suitability of a Functional Service Provider (FSP) Model for Clinical Trials

Clinical and regulatory teams face increased pressure to drive uninterrupted progress across the clinical development pathway. These teams routinely benefit from the support of an external partner who can minimize the risks of failure and missed...

READ MORE

2 min read

On-Demand Webinar: Decentralized Trial Solutions for Complex Clinical Trials

Decentralized clinical trials (DCTs) are becoming increasingly popular to optimize patient engagement and retention. At the same time, making DCTs a successful reality for the most complex studies is considered difficult given the many logistical and...

READ MORE